GenoTher Summit 2025: a key event to shape the future of gene therapy

Genethon, co-founder of GenoTher, is pleased to invite you to the first GenoTher Summit 2025 on June 11 in Evry, an international event at the heart of innovation in gene therapy. Organized as part of the official launch of GenoTher, the biocluster of excellence dedicated exclusively to gene therapy and France 2030 label, this summit will bring together all the players in the field for a day offering a wealth of exchanges, perspectives and collaborations.

A program to meet the challenges

• High-level scientific conferences
  Discover the latest advances in gene therapy, from basic research to the most recent clinical applications, with over 10 internationally renowned speakers.
• Networking & collaborations
  Connect with the ecosystem: researchers, investors, biotech companies, manufacturers, institutions and public decision-makers.
• Introducing GenoTher
  Attend the launch of GenoTher, an ambitious initiative to structure, accelerate and industrialize innovation in gene therapy.

GenoTher, a catalyst for innovation

Supported by the France 2030 plan, created by its founders – Genethon, Genopole, AP-HP, Inserm, Université d’Évry Paris-Saclay, Spark Therapeutics and Yposkesi – GenoTher aims to create a unique ecosystem to accelerate the development of gene therapy treatments, from research to industrialization. GenoTher’s action will unfold in several axes: 

• The development of specialized technology platforms, from research to industrial production.
• The development of next-generation gene therapy technologies, including cutting-edge approaches to in vivo and ex vivo genome editing, and RNA-based therapies, to extend their fields of application. 
• Disruptive innovation in biomanufacturing to drastically reduce the production costs of biomedicines and make them accessible to as many people as possible. 
• Sharing clinical excellence: new databases and innovative clinical trial models will accelerate the development of therapeutic solutions. 
• Training and skills development, through curricula dedicated to research, development, biomanufacturing and entrepreneurship.
• Entrepreneurial programs and support for the creation, incubation and development of high-potential start-ups to guarantee the creation and retention of excellence in France.

With over 2,000 researchers and clinicians, 10,000 publications, more than 2,000 patents and over 40 licensing agreements, GenoTher  is a major asset to position France as a leader in the development of innovative gene therapies.

Register now (free admission – registration required)

If you have any questions: events@genother.org

We look forward to seeing you there to help shape the future of gene therapy.